Omnia Health is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Binding site's latest protein system is being launched in the middle east that can process complex protein assays 40% faster than current systems

Article-Binding site's latest protein system is being launched in the middle east that can process complex protein assays 40% faster than current systems

Binding Site will unveil Optilite in Hall Z5, Stand B59 at the Medlab Exhibition in Dubai on 6th to 9thFebruary 2017, hosting product demonstrations for customers throughout the event. The company has spent more than four years developing Optilite in response to customer demand and the results are truly outstanding. In independent testing by 11 European clinical sites, Optilite has proven consistent efficiency and assay performance in real world lab conditions.

Charles de Rohan, CEO from Binding Site commented “The results we‘ve seen have been fantastic with labs reporting an average of 40 per cent decrease in the time it takes for them to run Optilite, compared with other market leading protein systems.”

Optilite is designed for workflow optimisation and stores up to 36 different reagents on board at any one time. As well as the Freelite®, Hevylite® and subclass assays, Optilite offers a comprehensive menu for special protein analysis.

Continuous loading of samples, reagents and consumables plus automatic re-dilution to end result, enables labs to maximise test throughput whilst minimising hands on time. With multilingual touch-screen technology and automatic barcode recognition, Optilite has been designed with the user in mind and at just 94 x 70 x 62cm, is one of the smallest systems on the market. It is so easy to use that minimum training is required and any level of staff can be confident with the results.

Optilite has robust antigen excess protection, with three different detection methods, that can be tailored to individual assays, thereby ensuring accurate and reliable results.

De Rohan added: “We wanted to bring simplicity to complex analytical processes. The result is Optilite, the latest innovation in special protein testing, which offers laboratories reliable results without compromising speed and efficiency.”




The Binding Site

With its origins in the Medical School of Birmingham University, Binding Site is now one of the largest independent providers for in vitro diagnostic tests and equipment in the UK. Exporting over 90% of its products overseas, it is the world leader in special protein testing.

Today it employs more than 700 people and has offices in all major markets worldwide.


Freelite is a polyclonal free light chain assay developed by the Binding Site to detect and monitor B-cell dyscrasias, including Multiple Myeloma (MM).

MM is characterised by the excess production of immunoglobulin free light chains (kappa or lambda) that are polymorphic in nature, Freelite  polyclonal antisera is able to recognise these variations ensuring sensitive and specific detection.

Freelite is: 

  • A highly sensitive and specific latex-based test that evaluates both free kappa and free lambda levels.
  • A quantitative, rapid and automated assay measuring only free kappa and free lambda light chains.
  • The only assay recommended by both national and international guidelines including the International Myeloma Working Group Guidelines for diagnosis and monitoring of MM and related disorders.
  • FDA cleared and CE marked as well as registered with a wide range of regulatory authorities.
Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.